Skye Bioscience Inc
Research Skye Bioscience Inc (SKYE) on Bullrun: market cap USD 6.94M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSKYE
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 6.94M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 10.79M
- Free cash flow-USD 7.12M
Valuation Snapshot
latest market cap is USD 6.94M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 55.92M | -USD 43.07M | n/a | -1.41 | USD 5.88M | USD 273.65K | USD 20.02M |
| FY2024 | USD 0 | -USD 26.57M | -USD 26.84M | n/a | -0.73 | USD 68.42M | USD 455.59K | USD 68.15M |
| FY2023 | USD 0 | -USD 37.64M | -USD 13.96M | n/a | -5.37 | USD 1.26M | USD 4.62M | -USD 2.13M |
| FY2022 | USD 0 | -USD 19.48M | -USD 12.77M | n/a | -8.77 | USD 1.24M | USD 1.98M | -USD 3.01M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 6.94M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 25.03M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 87.66M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 33.56M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 14.60M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 24.76M | n/a | n/a | n/a |
About Skye Bioscience Inc
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Skye Bioscience Inc's market cap?
Skye Bioscience Inc's market capitalization is USD 6.94M.
What does Skye Bioscience Inc do?
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.